Premium
Intramuscular testosterone and trenbolone enanthate elevates hemoglobin concentrations
Author(s) -
McCoy Sean C,
Yarrow Joshua F,
Conover Christine F,
Lipinska Judyta A,
Santillana Cesar,
Borst Stephen E
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.997.7
Subject(s) - medicine , endocrinology , prostate , testosterone (patch) , orchiectomy , androgen , prostate cancer , hemoglobin , chemistry , hormone , cancer
Testosterone enanthate (TE) increases serum testosterone (T), prostate mass, and hemoglobin (Hb) in orchidectomized (ORX) rodents. Trenbolone enanthate (TREN) is a synthetic analogue of T which does not undergo 5‐alpha reduction or aromatization; suggesting that it may increase Hb without inducing prostate enlargement. Our purpose was to determine whether TREN administration results in elevated circulating trenbolone (TR) and elevated Hb without prostate enlargement. Thirty‐five 10 month old male Brown Norway rats were randomized into Sham+vehicle (V), ORX+V, ORX+T, and ORX+TREN groups and received weekly drug injections for 42 days. Injections of TE, resulted in elevated serum concentrations of T compared to other treatments (p<0.05). Whereas, injections of TREN increased serum TR levels without increasing serum T (p<0.05). Prostate mass was 78% lower in ORX and 30% lower in TR groups vs. SHAM (p<0.05); while prostate mass in ORX+T was nearly double SHAM (p<0.05). Both T and TREN elevated Hb by 11% compared to ORX (p<0.05). Ultimately, ORX+TREN elevated Hb concentrations and reduced prostate mass; suggesting that TR may selectively activate androgen receptors. Supported by a VA Merit Award (SEB).